Research and Markets: PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022

Fri Jun 7, 2013 4:48am EDT

* Reuters is not responsible for the content in this press release.

Research and Markets: PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/3cvmhg/pharmapoint) has announced the addition of the "PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022" report to their offering.

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein.

The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients' survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems

The decrease in size of the overall market will be driven by generic erosion of Gleevec and Sprycel sales following their expected patent expiries in 2016 and 2020. Sales of Bosulif, which will be priced in line with second-generation TKIs, and Iclusig, which will be priced at a premium to the other TKIs, will help compensate for this loss of sales.

However, these drugs will be most commonly prescribed in patients who have already been treated with first- or second-generation TKIs; this will limit their uptake. GlobalData does not expect Synribo to be launched in France over the forecast period.

Scope

- Overview of the CML including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in France from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting France CML market.

For more information visit http://www.researchandmarkets.com/research/3cvmhg/pharmapoint

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.